Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 18/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872270 | 0.94 | GLP1R (0.49) | GLP1RPTGER4 | |
| SCHEMBL31140564 | 0.88 | PTGER4 (0.48) | GLP1RPTGER4 | |
| SCHEMBL23980750 | 0.86 | PTGER4 (0.52) | GLP1RPTGER4PDE10A | |
| SCHEMBL29770328 | 0.86 | PTGER4 (0.52) | GLP1RPTGER4PDE10A | |
| SCHEMBL28789071 | 0.86 | GLP1R (0.51) | GLP1RCYP2C8KCNH2HTR1APDE10A | |
| SCHEMBL28789072 | 0.86 | GLP1R (0.51) | GLP1RCYP2C8KCNH2HTR1APDE10A | |
| SCHEMBL29149774 | 0.84 | GLP1R (0.50) | GLP1RCYP2C8KCNH2HTR1A | |
| SCHEMBL29149777 | 0.84 | GLP1R (0.50) | GLP1RCYP2C8KCNH2HTR1A | |
| SCHEMBL20266409 | 0.83 | GLP1R (0.50) | GLP1R | |
| SCHEMBL24338858 | 0.83 | GLP1R (0.50) | GLP1RCYP2C8KCNH2HTR1APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | GLP1R 1/4885PTGER4 996/4885CYP2C8 3678/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GLP1R 1/4885PTGER4 996/4885CYP2C8 3678/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | GLP1R 1/4885PTGER4 996/4885CYP2C8 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.